Amylyx Pharmaceuticals, Inc.
AMLX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $258 | $990 | $2,458 | $1,046 |
| - Cash | $77 | $170 | $63 | $50 |
| + Debt | $2 | $4 | $6 | $0 |
| Enterprise Value | $182 | $824 | $2,401 | $995 |
| Revenue | $87 | $381 | $22 | $0 |
| % Growth | -77.1% | 1,612.9% | – | – |
| Gross Profit | $45 | $355 | $19 | $0 |
| % Margin | 51.8% | 93.3% | 86.5% | – |
| EBITDA | -$291 | $40 | -$201 | -$83 |
| % Margin | -333% | 10.5% | -903.5% | – |
| Net Income | -$302 | $49 | -$198 | -$88 |
| % Margin | -345.4% | 12.9% | -892.4% | – |
| EPS Diluted | -4.43 | 0.7 | -2.98 | -1.52 |
| % Growth | -732.9% | 123.5% | -96.1% | – |
| Operating Cash Flow | -$168 | $12 | -$180 | -$75 |
| Capital Expenditures | -$0 | -$1 | -$3 | -$0 |
| Free Cash Flow | -$168 | $11 | -$182 | -$75 |